Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH Agonist
Phase 2ActiveDevelopment Stage
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Nov 27, 2020 → Aug 25, 2027
About Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH Agonist
Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH Agonist is a phase 2 stage product being developed by Roche for Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04576455. Target conditions include Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04576455 | Phase 2 | Active |
Competing Products
20 competing products in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer